Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health has been awarded the 2026 Prix Galien USA Award for Best Medical Technology for its Shield blood test. This test is notable for being the first FDA-approved option for primary colorectal cancer screening. The award acknowledges the company's efforts in improving patient choice and increasing screening participation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health won the prestigious Prix Galien USA Award.
  • Shield blood test is recognized for colorectal cancer detection.
  • First FDA-approved test for primary CRC screening.
  • Achievement enhances patient choice and screening participation.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increasing screening participation for CRC. Established in 2007, the Prix Galien USA Awards recognize the leading scient

Frequently Asked Questions

What award did Guardant Health win?

Guardant Health won the 2026 Prix Galien USA Award for Best Medical Technology.

What is the Shield blood test used for?

The Shield blood test is used for colorectal cancer detection.

Is the Shield test FDA approved?

Yes, it is the first FDA-approved test for primary CRC screening.

What does the Prix Galien award recognize?

It recognizes achievements in expanding patient choice and screening participation.

ShareAdd on Google
Tags: GH Guardant Health Prix Galien colorectal cancer FDA approval medical technology
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~52 mo
Minimal dilution risk